Enovis Corporation (ENOV) – What Are Brokerages Thinking About This Stock?

Shares of Enovis Corporation (NYSE:ENOV) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $39.50.

A number of brokerages have weighed in on ENOV. Citizens Jmp dropped their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 2nd. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group restated a “buy” rating and issued a $44.00 price objective on shares of Enovis in a research report on Monday, October 5th. Canaccord Genuity Group reduced their price objective on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Finally, Citigroup reiterated a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert bought 2,660 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was bought at an average price of $18.80 per share, for a total transaction of $50,008.00. Following the completion of the transaction, the insider directly owned 63,898 shares in the company, valued at $1,201,282.40. The trade was a 4.34% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Damien Mcdonald purchased 13,035 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were purchased at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the purchase, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 23,293 shares of company stock valued at $449,599 over the last three months. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENOV. Paradigm Capital Management Inc. NY grew its holdings in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares during the period. River Road Asset Management LLC raised its position in shares of Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares during the last quarter. Private Management Group Inc. raised its position in shares of Enovis by 38.8% during the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after acquiring an additional 381,705 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Enovis by 38.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after acquiring an additional 287,687 shares during the last quarter. Finally, Invenomic Capital Management LP lifted its stake in shares of Enovis by 6.2% in the 4th quarter. Invenomic Capital Management LP now owns 756,717 shares of the company’s stock valued at $20,159,000 after purchasing an additional 44,048 shares during the period. 98.45% of the stock is owned by institutional investors.

Enovis Price Performance

Shares of ENOV stock opened at $17.72 on Wednesday. The stock’s fifty day moving average is $21.74 and its 200-day moving average is $23.29. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The stock has a market capitalization of $1.02 billion, a PE ratio of -0.92 and a beta of 1.37. Enovis has a 52 week low of $16.70 and a 52 week high of $34.28.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the company posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts expect that Enovis will post 3.15 EPS for the current fiscal year.

About Enovis

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.